CV Sciences, Inc. (OTCMKTS:CVSI – Get Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 86,300 shares, a growth of 112.6% from the May 31st total of 40,600 shares. Based on an average trading volume of 1,382,100 shares, the days-to-cover ratio is presently 0.1 days.
CV Sciences Stock Performance
CVSI stock opened at $0.06 on Friday. The stock’s 50 day simple moving average is $0.06 and its 200 day simple moving average is $0.04. CV Sciences has a 12-month low of $0.03 and a 12-month high of $0.10. The stock has a market capitalization of $10.60 million, a PE ratio of -2.93 and a beta of 0.60.
CV Sciences (OTCMKTS:CVSI – Get Free Report) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.01) earnings per share for the quarter. CV Sciences had a negative net margin of 20.38% and a negative return on equity of 102.29%. The company had revenue of $3.80 million for the quarter.
CV Sciences Company Profile
CV Sciences, Inc develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers.
Further Reading
- Five stocks we like better than CV Sciences
- High Flyers: 3 Natural Gas Stocks for March 2022
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Shanghai Stock Exchange Composite Index?
- MarketBeat Week in Review – 6/24 – 6/28
- CD Calculator: Certificate of Deposit Calculator
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.